Compare Hewlett Packard Enterprise Co (HPE) vs BIO-TECHNE Corp (TECH) Price & Performance

HPE stock trades at $72.115, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand and a recent $1.2 billion server order from Vultr. The technical outlook is bullish, with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth accelerated to $34.3 billion in 2025, but net income margin compressed to 0.16% due to higher costs, while 2026 projections show a rebound to $41.9 billion revenue and $2.8 billion net income.

The outlook remains positive given AI-driven guidance raises and analyst upgrades, but risks include execution on Juniper integration, debt levels rising to 29.48% of assets, and valuation multiples above sector averages. The stock offers growth exposure to AI infrastructure, yet investors face volatility near record highs.

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.